In summary, these data demonstrate the superior capacity of HSPC-derived BDCA1+ mDCs in expanding tumor-reactive CD8+ Tem cells, while the HSPC-derived pDCs appear to exhibit stronger potency to induce effector functions of antigen-experienced T cells. This evidence concerns the gene CD8A and neoplasm.